Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics

2021 ◽  
pp. 106871
Author(s):  
Jennifer S. Haas ◽  
David Cheng ◽  
Liyang Yu ◽  
Steven J. Atlas ◽  
Cheryl Clark ◽  
...  
2021 ◽  
Vol 17 ◽  
pp. 174550652110170
Author(s):  
Hannah Masson

Background: The Coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented upheaval within global healthcare systems and resulted in the temporary pausing of the National Health Service (NHS) Scotland Cervical Screening Programme. With several months of backlogs in appointments, there has not only been a reduction in primary samples being taken for human papilloma virus (HPV) testing but there have also been fewer women referred to colposcopy for investigation and treatment of precancerous or cancerous changes as a result. Encouraging uptake for cervical screening was always a priority before the pandemic, but it is even more important now, considering that the fears and barriers to screening that women may have are now exacerbated by COVID-19. Objectives: This article explores the impact of the pandemic on the uptake of cervical screening within NHS Ayrshire & Arran and evaluates potential strategies to improve uptake now and in future such as self-sampling and telemedicine. Methods: This article presents evidence-based literature and local health board data relating to cervical screening during the pandemic. Results: Human papilloma virus self-sampling carried out by the woman in her home has been shown to improve uptake, especially in non-attenders, whilst maintaining a high sensitivity and, crucially, reducing the need for face-to-face contact. Increased education is key to overcoming barriers women have to screening and telemedicine can strengthen engagement with women during this time. Conclusion: There are lessons to be learned from the pandemic, and we must use this opportunity to improve cervical screening uptake for the future.


2003 ◽  
Vol 15 (6) ◽  
pp. 473-477 ◽  
Author(s):  
Georgette Damasus-Awatai ◽  
Theresa Freeman-Wang

2021 ◽  
pp. 543-564
Author(s):  
Aggie Jokhan ◽  
Joyce Aburam ◽  
Emma Sinfield ◽  
Debra Holloway

This chapter begins with an overview of the NHS cervical screening programme, then describes ways of taking samples for liquid-based cytology. The colposcopy procedure is detailed, and indications for referral are listed. Subsequent treatment and follow-up are explained, and the role of the nurse in cervical screening in primary care is covered. The human papilloma virus, testing, and vaccines are included, along with the clinical features and management of cervical polyps, and cervical ectropion are explained.


2020 ◽  
pp. 096914132091827
Author(s):  
Alejandra Castanon

Objectives Introduction of new technologies into cervical screening programmes has allowed more efficient programmes with less resources. We present an overview of screening technologies introduced into the Cervical Screening Wales programme and their evolution over time. Methods Data from the programme’s statistical report were used to evaluate its performance over a 17-year period between 2001/02 and 2017/18. Results The introduction of liquid-based cytology has had a substantial impact on reducing inadequate sample rates and on increasing the positive predictive value of cytology. Inadequate rates have increased following the implementation of human papilloma virus testing as a triage test for cytology. Further knock-on effects on standard reporting ranges are expected following the introduction of human papilloma virus testing as the primary screening test. New performance standards have been introduced to better reflect the performance of the programme at a time when disease prevalence is expected to fall as women vaccinated against human papilloma virus reach screening age. Conclusions Improvements to this cervical cancer screening programme as illustrated through performance indicator ranges suggest a major role played by technology.


2016 ◽  
pp. 100-102
Author(s):  
O. Rykova ◽  

The article presents modern laboratory aspects of cervical screening, which include assessment of infection with human papillomavirus (HPV) high carcinogenic risk. Key words: cervical cancer, cervical screening, traditional cytology, liquid-based cytology, PAP-test, human papilloma virus.


Author(s):  
H. A. Haruna ◽  
S. O. Olonitola ◽  
M. Aminu

Aim: To determine the sero-prevalence of Human Papilloma Virus type 16(HPV-16) immunoglobulin G antibodies and its association with socio-demographic features of women attending some clinics in Lokoja, Kogi State, Nigeria. Study Design: Hospital based cross sectional study. Place and Duration of Study: Kogi State specialist hospital and Federal medical Centre, Lokoja. Kogi State, Nigeria, between June and October, 2015. Methodology: We included 400 participants (380 pregnant and 20 non pregnant women; age range 15 to 45 years) attending the hospitals during the duration of the research. Serum samples were analysed for human papilloma virus type 16 IgG using the Enzyme Linked Immunosorbent Assay and questionnaire was also administered to obtain demographic features of the participants. Results: The prevalence of human papilloma virus type 16 IgG antibodies was found to be 10%. The occurrence of IgG antibodies to human papilloma virus was found to be statistically associated with educational status and occupation (P = 0.020 and 0.036 respectively). Conclusion: The prevalence of human papilloma virus was high. Cervical screening centres should be established in all areas of the state and awareness campaigns should be organized to afford young women the knowledge and dangers of cervical cancer and preventive measures.


Sign in / Sign up

Export Citation Format

Share Document